House Bill 233
150th General Assembly (2019 - 2020)
Bill Progress
Out of Committee 6/19/19
The General Assembly has ended, the current status is the final status.
Bill Details
6/18/19
AN ACT TO AMEND TITLE 16 OF THE DELAWARE CODE RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.
This Act expands the definition of “prescription drug order” to include electronic prescribing and makes Gabapentin a Schedule V controlled substance. Gabapentin is a prescription medication which is used to treat partial seizures and neuropathic pain. However, Gabapentin is also used to increase the effects of opioids, which potentially increases the risk of overdose death when used in combination with opioids. Gabapentin has become a drug of abuse with users reporting effects such as euphoria, a marijuana-like high, and other users describing their state after taking the medication to be zombie-like. The United States has seen substantial increases in the rate of Gabapentin prescribing and abuse. Several states, including Kentucky, Ohio, and West Virginia, have already classified Gabapentin as a Schedule V controlled substance. Classifying Gabapentin as a Schedule V controlled substance in Delaware will permit the State to monitor the prescription of the drug and address issues of abuse.
N/A
N/A
Not Required
Takes effect upon being signed into law
N/A
Amendments
Committee Reports
Roll Calls
Actions History
Legislation Detail Feeds
Roll Call Details
Committee Report Details
Favorable:
On its Merits:
Unfavorable: